Overview

CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat

Status:
Completed
Trial end date:
2021-04-15
Target enrollment:
Participant gender:
Summary
This trial will compare two effective therapies, allopurinol and febuxostat, to lower serum uric acid and therefore prevent further gout attacks. These therapies have never been compared at appropriate doses. Further, they will be studied in patients with kidney disease for the first time.
Phase:
Phase 4
Details
Lead Sponsor:
VA Office of Research and Development
Treatments:
Allopurinol
Febuxostat
Uric Acid